Orion saw the highest growth of 128% in patent filings and 399% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 86% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Orion‘s patent filings and grants. Buy the databook here.
Orion has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 12% filings and 22% grants. The Australia(AU), Israel(IL), Brazil(BR), and Colombia(CO) patent Office are among the top ten patent offices where Orion is filings its patents. Among the top granted patent authorities, Orion has 22% of its grants in European Patent Office(EPO), 11% in Australia(AU) and 11% in Israel(IL).
Patents related to electronic medical record (emr) systems and healthtech lead Orion's portfolio
Orion has the highest number of patents in electronic medical record (emr) systems followed by, healthtech and connected care. For electronic medical record (emr) systems, nearly 11% of patents were filed and no patents were granted in Q4 2023.
Prostate cancer related patents lead Orion portfolio followed by packaging, and breast cancer
Orion has highest number of patents in prostate cancer followed by packaging, breast cancer, pain, and phobia.
For comprehensive analysis of Orion's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.